 | Up a level |
Journal Article
Drilon, Alexander, Siena, Salvatore, Dziadziuszko, Rafal 
ORCID: 0000-0001-8080-9843, Barlesi, Fabrice, Krebs, Matthew G., Shaw, Alice T., de Braud, Filippo, Rolfo, Christian, Ahn, Myung-Ju, Wolf, Juergen, Seto, Takashi, Cho, Byoung Chul, Patel, Manish R., Chiu, Chao-Hua, John, Thomas, Goto, Koichi, Karapetis, Christos S., Arkenau, Hendrick-Tobias, Kim, Sang-We, Ohe, Yuichiro, Li, Yu-Chung, Chae, Young K., Chung, Christine H., Otterson, Gregory A., Murakami, Haruyasu, Lin, Chia-Chi, Tan, Daniel S. W., Prenen, Hans, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R. and Doebele, Robert C.
(2020).
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol., 21 (2).
S. 261 - 271.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Tan, Daniel S. W., Kim, Sang-We, Aix, Santiago Ponce, Sequist, Lecia, V, Smit, Egbert F., Yang, James C. H., Hida, Toyoaki, Toyozawa, Ryo, Felip, Enriqueta, Wolf, Juergen, Grohe, Christian, Leighl, Natasha B., Riely, Gregory, Cui, Xiaoming, Zou, Mike, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2022). Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur. J. Cancer, 172. S. 276 - 287. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Tan, Daniel Shao-Weng, Leighl, Natasha B., Yang, James Chih-Hsin, Riely, Gregory J., Sequist, Lecia, V, Toyozawa, Ryo, Wolf, Juergen, Felip, Enriqueta, Kim, Sang-We, Aix, Santiago Ponce, Smit, Egbert F., Hida, Toyoaki, Grohe, Christian, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2020). Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755